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Transscleral delivery of timolol maleate and dexamethasone phosphate, both low molecular 
weight compounds, was achieved with anodal and cathodal iontophoresis, respectively. 
Increased current doses produced proportional increases in transport. In comparison, anodal 
iontophoresis of vancomycin hydrochloride, a glycopeptide, exhibited a non‐linear relationship 
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The fundamental understanding of ocular drug delivery using iontophoresis is not at the same 
level as that for transdermal electrotransport. Research has therefore been undertaken to 
characterise the electrical properties of the sclera (charge, permselectivity, isoelectric point 
(pI)) and to determine the basics of iontophoretic transport of model neutral, cationic, and 
anionic species (respectively, mannitol, timolol, and dexamethasone phosphate). Like the skin, 
the sclera supports a net negative charge under physiological pH conditions and has a pI 
between 3.5 and 4. Equally, the principles of trans‐scleral iontophoretic transport of low 
molecular weight compounds are consistent with those observed for skin. Iontophoretic 
delivery of timolol and dexamethasone phosphate was proportional to applied current and 
drug concentration, and trans‐scleral iontophoresis in rabbits led to enhanced intraocular 
levels of these compounds compared to passive delivery. The behaviour of higher molecular 
weight species such as peptide drugs and other biopharmaceuticals (e.g., proteins and 
oligonucleotides) has not been fully characterised. Further work has been undertaken, 
therefore, to examine the trans‐scleral iontophoresis of vancomycin, a glycopeptide antibiotic 
with a relatively high molecular weight of 1448 Da. It was indeed possible to deliver 
vancomycin by iontophoresis but trans‐scleral transport did not increase linearly with either 
increasing current density or peptide concentration. 
Keywords:	 ocular iontophoresis; trans‐scleral; timolol; dexamethasone phosphate; 
vancomycin 
                            
                           
                         
                                   
                           
                                   
                     
                         
                         
                               
                       
                         
                       
                         
                     
                               
                         
                         
                   
                         
                   
                           
                   
                         
                       
                     
                           
                               
                           
                   
                           
                             
                     
                       
                           
                     
                   
                             
                     
          
                     
                                 
                         
                               
                         
                           
         
INTRODUCTION 
Drug delivery to the eye to treat ocular disease principally involves either multiple topical 
application of formulations to the ocular surface, or injections directly into the ocular tissues 
(i.e. intra‐vitreal, sub‐conjunctival). The former is characterised by very low efficiency, in that 
only a few percent of the applied dose is ever absorbed [1‐3], while the invasive nature of the 
latter approach is very clear [4‐6]. Identification of an alternative method, which can deliver 
drugs to various compartments of the eye (from the ocular surface to the very back of the eye) 
would constitute an important development and satisfy obvious unmet medical need. 
Iontophoresis is a technique that has been examined in‐depth with respect to transdermal 
drug delivery and has been shown capable of transporting chemicals of widely divergent 
properties across the skin at levels that are impossible to attain by passive diffusion [7]. In 
particular, iontophoresis has expanded the range of transdermal drug candidates to include 
charged and water‐soluble species as well as allowing peptides of molecular weights greater 
than 1000 Daltons to be delivered. Enhanced transdermal transport induced by iontophoresis 
involves mechanisms whereby the applied electrical field acts on the molecule without causing 
detrimental perturbation of the tissues, and the correlation demonstrated between applied 
current and drug flux offers a means to precisely and flexibly control the delivery profile. It 
follows, therefore, that there is potential to explore and exploit applications of iontophoresis 
to drug delivery across other epithelial barriers, including the eye, and this opportunity 
constitutes the focus of the research reported in this paper. 
Thus, the long‐term objective is to advance the basic understanding of ocular iontophoresis 
[8,9]; specifically, to characterize the barrier’s permselectivity and to establish structure‐
transport relationships. In the first part of this study, the electrotransport of neutral, cationic, 
and anionic compounds (mannitol, timolol, and dexamethasone phosphate, respectively) have 
been examined across rabbit sclera. Mannitol was used to measure electroosmosis and to 
determine the isoelectric point of the ocular barrier. Dexamethasone phosphate and timolol 
maleate, two widely used ophthalmic drugs, were chosen, respectively, as negatively‐ and 
positively‐charged agents. It was a further goal to examine whether compound flux across the 
sclera can be optimized using the same strategies that have proven successful for skin [10] and 
to confirm that linear 'flux‐current' relationships also apply at the higher current densities used 
in ocular delivery. Trans‐scleral iontophoretic delivery of dexamethasone phosphate and 
timolol maleate was also evaluated in vivo in rabbits and compared to passive delivery. 
While it is generally true that the transdermal electrotransport of small compounds (< 500 Da) 
increases linearly with current density and donor concentration [10,11], iontophoresis of 
certain cationic peptides has displayed a non‐linear dependence upon concentration in the 
driving electrode chamber due, it is believed, to an association of the molecule with 
negatively‐charged sites on the skin, altering its permselectivity and decreasing the 
electroosmotic contribution to transport [12]. Recently, trans‐scleral iontophoresis of neutral, 
high molecular weight dextrans (MW between 4.4 and 120 kDa) in vitro has been reported 
[13]. However, the relationships between iontophoretic flux and either driving concentration 
or current were not explored. 
Delivery of macromolecules (such as proteins and oligonucleotides) at therapeutically useful 
levels to the back of eye is a major challenge for the treatment of posterior segment diseases. 
To explore the feasibility of such a strategy, vancomycin, a structurally complex glycopeptide, 
which is positively charged at physiological pH [14], was chosen, in the second phase of this 
work, as a model compound to explore the efficiency of trans‐scleral delivery via 
iontophoresis, and to evaluate if its transport depends on the applied current and/or the 




                       
                           
                     
                   
                     
                     
                     
           
                   
                       
                             
                         
                       
                             
                             
                   
 
                   
                           
                                 
                       
                                 
            
                             
                             
                       
                           
                     
  
   
                           
                               
                                 
                                 
                                 
                               
                           





[14C]‐Mannitol (specific activity 200 µCi/mL) was obtained from Amersham, plc (Little Chalfont, 
UK). Ultima Gold XR, Hionic Fluor and Solvable were obtained from Perkin Elmer (Waltham, 
MA, USA). Mannitol (>98%), timolol maleate (>98%), and dexamethasone sodium phosphate 
(>98%) were purchased from Sigma‐Aldrich Co. (Gillingham, UK). Dexamethasone phosphate 
(acid form) was manufactured by Dalton Chemical Laboratories (Toronto, ON, Canada). 
Dexamethasone‐4,6 alpha, 21, 21‐d4 was purchased from C/D/N Isotopes (Pointe‐Claire, QC, 
Canada). Vancomycin hydrochloride (94.2%) was from Alexis Biochemicals (Exeter, UK). HEPES 
(N‐2‐hydroxy‐ethylpiperazine‐N‐2‐etanosulfonic acid), sodium chloride, sodium dihydrogen 
phosphate, potassium dihydrogen phosphate, triethylamine, and Tris were supplied from 
Acros (Geel, Belgium). Ammonium acetate (ACS grade) was purchased from Sigma‐Aldrich (St. 
Louis, MO, USA) and ammonium formate was supplied by Alfa Aesar (Ward Hill, MA, USA). 
Methanol (HPLC grade), acetonitrile (HPLC grade), and acetic acid were from Fischer Scientific 
(Loughborough, UK). Highly purified deionized water (resistivity >18.2 MΩ.cm) was used to 
prepare all solutions used for the in vitro experiments and for HPLC analysis. Sterile injection 
grade water (Baxter Healthcare, Deerfield, IL, USA) was used to prepare drug solutions for the 
in vivo studies. All other chemicals were of analytical grade. 
General 
Trans‐scleral iontophoresis studies were performed in side‐by‐side diffusion cells (PermeGear, 
Hellertown, PA, USA). The sclera was obtained from albino rabbit eyes (Harland, Bicester, UK), 
which were stored for no more than 3 days post‐harvesting in PBS at 4°C before use. Scleral 
tissue was freed from the conjuctiva, extraocular muscles and choroid/retina. The sclera 
(transport area = 0.2 cm2) was clamped between the two half‐cells (volume = 4 mL), with the 
conjunctival side facing the drug solution. 
Ag/AgCl electrodes were used to deliver the constant current, which was provided by a power 
supply (either an APH 1000M from Kepco Inc., Flushing, NY, USA or a Yokogava 7651 
Programmable DC source, Woodburn Green, UK). Each experiment was performed at ambient 
temperature in at least quadruplicate, using the excised sclera from at least two different 
rabbits. Appropriate passive, no‐current controls were also performed for all donor 
concentrations. 
Mannitol electrotransport 
Anodal and cathodal iontophoresis was performed at 1 mA (5.1 mA/cm2). The current was 
applied for 2 hours with sampling of the receptor phase every 20 minutes. The donor solutions 
comprised 1 mM mannitol (spiked with 14C) in 154 mM NaCl and buffered with 25 mM HEPES 
to pH 3.0, 3.5, 4.5, 5.5, 6.5 or 7.4. The pH 3.5 and 7.4 experiments were performed 
sequentially using the same sclera; likewise, the pH 4.5 and 6.5, and the pH 3.0 and 5.5, 
experiments were also carried out sequentially using the same barrier. At the end of the first 
half of each experiment, the donor and receptor chambers were fully emptied, cleaned, and 
refilled. In all cases, the receptor solution was identical to the donor solution except that it did 
not contain mannitol. 
           
                           
                           
                               
                           
                             
                               
                         
                               
                                     
 
                           
                             
                               
                         
                           
                                 
         
           
                           
                                   
                             
                           
                               
                       
         
                                 
                       
                           
                                 
            
                         
                           
                        
                               
                               
                            
                             
                 
     
                           
                               
                   
                             
Anodal trans‐scleral iontophoresis of timolol maleate 
Anodal iontophoresis was carried out at 1 mA (5.1 mA/cm2). Trans‐scleral delivery from three 
donor solutions was first examined. All contained 0.25% w/v timolol maleate (3.4 mg/mL) but 
differed in the concentration of background (NaCl) electrolyte: 10, 77 and 154 mM. The pH of 
the donor solutions was 4.2 ‐ 4.3. At the higher levels of background electrolyte, iontophoresis 
was performed over a 2‐hour period; when the NaCl concentration was 10 mM, current was 
passed for only 70 minutes in total due to the consumption of chloride by the Ag/AgCl 
electrochemistry. In all cases, the receptor solution was phosphate‐buffered saline (PBS) at pH 
7.4 (140 mM NaCl). Samples (1 mL) of the receptor phase were withdrawn (and replaced with 
fresh buffer) every 10 minutes for 1.5 hr and then again at 2 hours and reserved for assay of 
timolol. 
Ocular iontophoresis at the same current density as before was then assessed from donor 
solutions containing either 0.05, 0.25 or 0.5% w/v timolol maleate (i.e., 1.57, 7.86 and 15.7 
mM, respectively), buffered to pH 7.0 with 25 mM Tris containing 77 mM NaCl. Current was 
again delivered for 2 hours and the receptor phase was sampled as before. 
Finally, using the identical 0.5% w/v drug solution and receptor phase, the electrotransport of 
timolol was determined at applied currents of 0.5, 1.0 and 2.0 mA (2.55, 5.1 or 10.2 mA/cm‐2) 
using the method outlined above. 
Cathodal trans‐scleral iontophoresis of dexamethasone phosphate 
Cathodal iontophoresis was conducted for 1 hour using as donor solutions and applied current 
either (a) 0.4% w/v dexamethasone phosphate in water at 0.5, 1, and 2 mA (2.55, 5.1 or 10.2 
mA/cm‐2), or (b) 0.1, 0.4, 1.0 and 2.0% w/v drug (corresponding, respectively, to 1.94, 7.74, 
19.4 and 38.7 mM) at 1 mA (5.1 mA/cm2). The receptor solution was phosphate‐buffered 
saline at pH 7.4. Samples (1 mL) of the receptor phase were withdrawn (and replaced with 
fresh buffer) every 10 minutes and reserved for assay of the drug. 
Anodal trans‐scleral iontophoresis of vancomycin 
The current was applied for 2 hours and the receptor phase was sampled every 20 minutes for 
delivered peptide. The electrodes were separated from their respective donor and receptor 
solutions by salt bridges to prevent peptide adsorption on Ag/AgCl. The salt bridges comprised 
3% agarose in solutions of 100 mM Tris/Trizma® HCl (pH 7.0) and 25 mM Tris/Trizma® HCl (pH 
7.4) for anode and cathode, respectively. 
The receptor (cathode) compartment contained a solution of 25 mM Tris/Trizma® HCl normal 
saline buffered to pH 7.4. The background electrolyte in the anode compartment was a 
solution of 100 mM Tris/Trizma® HCl normal saline buffered to pH 7.0. 
The effect of vancomycin concentration (0.1, 1.0, 5.0 and 10 mM) in the donor (anode) on 
trans‐scleral delivery of the peptide was first examined at an applied current of 1 mA (5.1 
mA/cm2). The impact of current on vancomycin iontophoresis was then determined at 0.5, 1, 
and 2 mA (2.55, 5.1 and 10.2 mA/cm‐2, respectively); for these experiments, the donor solution 
was 5 mM vancomycin in 20 mM Tris/Trizma® HCl. 
In Vivo Experiments 
Female New Zealand white rabbits weighing 3.0 to 3.5 kg (Millbrook Breeding Labs, Amherst, 
MA, USA) were used. Animals were acclimated for at least 3 days before the study was 
initiated. All experiments were performed under identical environmental conditions, with 
adherence to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research 
                     
   
                     
                     
                       
                         
                                 
                               
                               
                               
                           
                           
                                     
                          
 
                             
                     
                       
                       
                                 
                         
                             
 
                         
                               
                     
                               
                               
                         
           
                         
                                 
                             
                                     
                           
                                 
                           
                           
and with approval from EyeGate Pharmaceuticals’ Institutional Animal Care and Use 
Committee (IACUC). 
The iontophoretic delivery system consisted of an ocular applicator (Eyegate Pharmaceuticals, 
Waltham, MA, USA), two 1.5”x2” Tricot rectangular snap return electrodes (Pepin 
Manufacturing Inc., Lake City, MN, USA), a Yokagawa GS610 low‐voltage DC generator 
(Yokogawa Corp., Newnan, GA, USA), electrical wires and connectors. The ocular applicator is 
annular in shape, and designed to fit over the limbus of the human eye, to allow direct 
transscleral delivery. The inner diameter of the applicator (14 mm) is the same diameter as 
the average human cornea to help facilitate centering of the device on the eye. The active 
contact surface area between the eye and the applicator is approximately 1 cm2 and consists of 
soft polyurethane hydrophilic foam that serves as the reservoir for drug solution to be 
delivered; the foam reservoir held approximately 500 µL of drug solution. The electrode is 
inert and annular in shape to match the shape and size of the foam (Figure 1). In New Zealand 
White rabbits the device fits over the limbus similar to that in humans. 
Figure 1:	 Schematic diagram of the ocular iontophoretic drug delivery device used in the in 
vivo experiments. The annular device comprises the following main elements: (1) 
proximal part which provides rigid support; (2) source connector pin between the 
current generator and the electrode; (3) electrode which transfers current to the 
formulation reservoir; (4) reservoir (17 mm OD x 14 mm ID x 3 mm H) which contains 
a polyurethane‐based foam insert saturated with a solution of the drug to be 
delivered; and (5) distal part, which is a soft plastic that interfaces with the eye. 
Animals were anesthetized by intramuscular injection of xylazine (5 mg/kg; IVX Animal Health 
Inc., St. Joseph, MO, USA) and ketamine (35 mg/kg; Fort Dodge Animal Health, Fort Dodge, IA, 
USA), and topical anesthetic (0.5% proparacaine hydrochloride; Bausch and Lomb; Rochester, 
NY, USA) was applied to each eye. The ocular device was loaded with the appropriate drug 
solution and placed on the animal’s eye; two return electrodes were attached to the ears, and 
all were connected to the low‐voltage generator. The applicator and return electrodes were 
disposable and discarded after each treatment. 
For experiments evaluating the anodal delivery of timolol, animals received a single anodal 
iontophoresis dose of a 4% w/v solution of timolol maleate at 4 mA (corresponding to about 4 
mA/cm2) for approximately 5 minutes (20 mA.min) (n = 4). Animals in the control group 
received a single drop (50 μL) of timolol maleate 4% w/v solution on each eye (n = 4). With 
respect to dexamethasone, animals received a single cathodal iontophoretic dose of a 4% w/v 
solution of dexamethasone phosphate (acid form) at 2, 4, or 6 mA (equal to approximately 2, 4 
or 6 mA/cm2, respectively) for approximately 5 minutes (10, 20, and 30 mA.min respectively) 
(n = 3). Animals were sacrificed within 15 minutes post‐treatment by intravenous overdose of 
                       
                           
 
   
                       
                             
                         
                          
                       
                       
                       
                         
                       
                             
                             
                           
                               
                 
                     
                                       
                       
                       
                           
                           
                         
                     
                               
                               
             
                           
                               
                           
                                 
                             
                       
   
                     
                         
                         
                       
     
                         
                         
                                 
                               
     
sodium pentobarbital (Euthasol®, Virbac Inc., Fort Worth, TX, USA). Ocular tissues were 
immediately harvested and snap frozen on dry ice. Samples were then stored at  ‐80oC until 
processed. 
Analytical chemistry 
Receptor phase samples from the mannitol experiments were mixed with scintillation cocktail 
(Ultima Gold XR, Perkin Elmer, Shelton USA) and analysed for 14C in a liquid scintillation 
counter (Perkin Elmer, Liquid Scintillation Analyzer, Tri‐Carb 2008 TR, IL, USA). The measured 
dpm values were transformed into a molar mannitol flux in the normal way. 
Timolol maleate [15] and dexamethasone phosphate [16] were analysed by high pressure 
liquid chromatography (HPLC). The system comprised either a Jasco (Great Dunmow, UK) 
model PU‐2080 Plus pump, model AS‐2051 Plus autosampler, and UV detector (Model UV‐
2975 Plus), or a Dionex (Camberley, UK) ASI‐100 automated sampler injector, P680 pump, TCC‐
100 thermostated column compartment, and PDA‐100 diode array detector. The mobile phase 
for timolol maleate was a 25:75 v/v mixture of acetonitrile and an aqueous phase comprising 
2.8 mL/L triethylamine and 10 mL/L acetic acid at pH 4.0. For dexamethasone phosphate, the 
mobile phase was 0.15 M potassium dihydrogen phosphate buffer at pH 2.0 and acetonitrile 
(70:30 v/v). Flow rates were 1.0 and 0.75 mL/min, and injection volumes were 20 and 25  μL, 
for timolol maleate and dexamethasone phosphate, respectively. Chromatographic resolution 
of timolol maleate and dexamethasone phosphate was performed on C18 reverse‐phase 
columns (5 µm, 150 mm x 4.6 mm (Acclaim, UK), and 5 µm, 125 mm x 4.0 mm (HiChrom, UK), 
respectively), and guard columns with the same properties thermostated at 25°C. Timolol 
maleate and dexamethasone phosphate were determined from their UV absorbances at 294 
and 240 nm, respectively. Standard stock solutions of the two compounds were prepared in 
methanol and appropriate dilutions were made with PBS at pH 7.4. Calibration curves were 
established in the ranges of 0.05 ‐ 100 μg.mL‐1 (r2>0.999) and 0.02 ‐ 100 μg.mL‐1 (r2>0.999) for 
timolol maleate and dexamethasone phosphate, respectively. Accuracy of the HPLC methods, 
expressed as a percentage of mean recovery, ranged from 95% to 105%, and precision had a 
relative standard deviation (RSD) of less than 3%. The limit of quantitation was 0.05 µg.mL‐1 for 
timolol and 0.02 µg.mL‐1 for dexamethasone phosphate. 
Samples of the receptor phase were assayed for vancomycin [17] by HPLC (Jasco, Great 
Dunmow, UK). The analytical column was C18 (150 x 4.6 mm, 5 µm, Dionex) and was 
maintained at 30 °C. The mobile phase consisted of 5 mM potassium dihydrogen phosphate 
solution (pH 2.8) and acetonitrile in a ratio of 90:10. The flow rate was 1 mL/min. Vancomycin 
was determined from its UV absorbance at 229 nm. The relative standard deviation (RSD) of 
repeatability was less than 5% and the quantitation limit was 0.25 µg/mL. 
Bioanalytical Chemistry 
Tissue samples were analyzed for timolol maleate content by liquid chromatography‐mass 
spectrometry (LC‐MS). The LC comprised an Agilent 1200 autosampler with a 1200 quaternary 
pump and column compartment (Agilent Technologies, Santa Clara, CA, USA). The MS system 
was an Agilent 6410 triple quadrupole operating under ElectroSpray Ionization (ESI) conditions 
in positive mode. 
The chromatographic conditions for timolol maleate used 80:20 v/v mixture of 20 mM 
ammonium formate at pH 3.2 (mobile phase A) and acetonitrile/methanol (80:20 v/v) (as 
mobile phase B) in isocratic mode on a Waters Sunfire 3.5  μm C18, 3 x 100 mm column 
(Waters Corporation, Milford, MA, USA), at a flow rate of 0.8 mL/min and with an injection 
volume of 10 μL. 
                               
                               
                             
             
                         
                       
                       
         
                   
                       
                       
                 
                           
                     
                         
                   
                         
                              
                             
                           
                   
                     
                             
                 
   
                             
                             
                           
                         
                             
                 
 
 
Ionization was performed in Single Ion Monitoring (SIM) mode at a m/z of 317.2 for timolol 
maleate in the dissociated form. Care was taken to ensure the least carryover for the system 
by using an injection program to limit any possible contribution from drug remaining in the 
injection valve. The analytical range was 0.01 ‐ 10 μg/mL. 
All tissues except for aqueous humour and vitreous were homogenized on a Qiagen 
TissueLyser II (Qiagen, Valencia, CA, USA) followed by protein precipitation with acetonitrile. 
After centrifugation, samples were dried in a Savant SPD1010 Speedvac® (Thermo Scientific, 
Waltham, MA, USA) and reconstituted. 
Ocular tissue samples were analyzed for dexamethasone phosphate and dexamethasone 
content by LC‐MS/MS using a Sciex API‐4000 mass spectrometer (Applied Biosystems, Foster 
City, CA, USA) running a Multiple Reaction Monitoring (MRM) LC‐MS/MS method for 
simultaneous quantitation of dexamethasone and dexamethasone phosphate. Ocular tissue 
samples were weighed and mixed with homogenization solution (1:1 v/v MeOH:water) in a 1:9 
w/v ratio and homogenized using an Omni hand‐held homogenization device (Omni 
International, Kennesaw, GA, USA), for conjunctival tissue, or a Qiagen TissueLyser II, followed 
by protein precipitation with acetonitrile. Dexamethasone and dexamethasone phosphate 
were resolved using an ammonium acetate – methanol gradient method and a Thermo 
AQUASIL C18, 2.0 x 50 mm column (Thermo Scientific, Waltham, MA, USA). Standard curves of 
1 ng/mL to 1000 ng/mL for both analytes were run in each tissue matrix using dexamethasone‐
d4 as an internal standard. Concentrations measured in ocular tissue samples were reported in 
nanograms per millilitre of homogenization solution for both dexamethasone and 
dexamethasone phosphate; data were then converted to nanomoles of dexamethasone per 
gram of tissue or nanomoles of dexamethasone per millilitre of aqueous humour, or to the 
total amount of dexamethasone delivered to each tissue compartment. 
Data analysis 
A minimum of 4 replicates was performed for each in vitro experiment. All results are 
expressed in terms of the mean ± standard deviation. Graph Pad Prism 4.0 Software (San 
Diego, USA) was used for data and statistical analyses; the latter involved one‐way ANOVA, 
followed by the Student‐Newman‐Keuls test. Fluxes were calculated from the slope of the 
cumulative amount delivered as a function of time for each replicate. A minimum of 3 
replicates was performed for each in vivo experiment. 
     
                           
                       
        
                                   
                           
                         
                                 
                     







                             
                     
                    
                     
                             
         
                           
                                 
                           
RESULTS AND DISCUSSION 
The passive transport of mannitol, timolol, and dexamethasone through the sclera, under all in 
vitro experimental conditions, was rather small compared to that achieved with iontophoresis 
(see Supplementary Table S1). 
Electrotransport of mannitol in vitro as a function of pH is shown in the upper panel of Figure 
2. At pH 7.4, transport in the anode‐to‐cathode direction was significantly greater than that 
from cathode‐to‐anode. At pH 3, the situation was reversed. Broadly speaking, this behaviour 
is not unlike skin [18], and indicates that the rabbit sclera, at physiological pH, is a net 
negatively‐charged membrane, permselective to cations, as has been previously deduced [8] 
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Figure 2: Upper panel: Electroosmotic flux of mannitol across rabbit sclera (area = 0.2 cm2) 
after 2 h of iontophoresis in the anode‐to‐cathode (open circles) and cathode‐to‐
anode (filled circles) directions (mean ± SD, n = 4). 
Lower panel: Anodal‐to‐cathodal flux ratio of mannitol electroosmosis as a function 
of pH. The intersection of the line through the data with the x‐axis indicates the 
approximate pI of rabbit sclera. 
Based on the pH dependence of the anodal and cathodal electrotransport of mannitol, the 
isoelectric point (pI) of rabbit sclera is between 3.5 and 4 (Figure 2, lower panel), slightly lower 
than that of mammalian skin [18,19]. The deduced electroosmotic flow (= mannitol flux ÷ 
                           
                     
                           
                                  
                           
                             
                             
                       
                           
                             
                               








                             
                         
            
                             
                               
                   
                               
                           
                         
                                 
                           
                               
                     
                       
                         
                        
                             
                     
donor concentration) is ~10  μL/h.mA, a value about 6  ‐ 7 times that observed across human 
skin (~1.6  μL/h.mA under similar conditions when approximately 1/10th the current was 
applied [18] and in reasonable agreement with that which has been reported elsewhere for 
human and pig sclera [13]. It is noteworthy that the passive flux of mannitol across the scleral 
membrane is higher than that observed across skin, and this observation (which has been 
reported before [9]) has been attributed to the greater porosity of the ocular tissue [20]. 
In vitro iontophoresis of timolol was efficient, and the transport number of the drug was 
enhanced by reducing competition from the background electrolyte (Figure 3). From Faraday’s 
law, the iontophoretic flux of the drug, and the applied current, the approximate transport 
numbers (calculated from the fluxes at 60 minutes of iontophoresis) of timolol from 10, 77, 
and 154 mM NaCl solutions (corresponding to molar fractions of drug in the three cases of 
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Figure 3: Cumulative delivery of timolol from a 0.25% w/v solution by anodal iontophoresis at 
1 mA (5.1 mA/cm2) as a function of time and background electrolyte concentration 
(mean ± SD, n = 4). 
The experiment at the lowest NaCl concentration could not be continued for 2 hours because 
of chloride depletion in the anode solution. In practice, this may not pose a significant problem 
as the duration of ocular iontophoresis is typically much shorter. 
At a fixed applied current of 1 mA, the iontophoretic delivery of timolol from a solution 
containing 77 mM NaCl increased linearly with drug concentration as expected (Figure 4). The 
fluxes at 60 minutes of iontophoresis from donor anodal solutions containing 0.05%, 0.25% 
and 0.50% w/v timolol maleate were 1.4 (± 0.4), 7.1 (± 2.3) and 12.8 (± 0.7) nmol.min‐1, 
respectively. Similarly, when the timolol concentration was held constant (0.25% w/v in 77 mM 
NaCl) and the applied current was allowed to increase from 0.5 to 2.0 mA, the electrotransport 
of the drug responded in a directly proportional fashion (Figure 5). 
Unlike the somewhat linear dependence of timolol electrotransport on molar fraction, an 
earlier study [9] with tetraethyl ammonium chloride revealed only a 4‐fold increase in 
transference number despite an approximately 65‐fold increase in concentration of the cation. 
In the latter case, however, (and distinct from the situation with timolol – See Supplementary 
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Figure 4:	 Cumulative delivery of timolol by anodal iontophoresis at 1 mA (5.1 mA/cm2) as a 
function of time and concentration from solutions containing 77 mM NaCl (mean ± 
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Figure 5:	 Steady‐state iontophoretic fluxes of timolol maleate (dashed line) (r2 = 0.989) and 
dexamethasone phosphate (solid line) (r2 = 0.997) across rabbit sclera (area = 0.2 
cm2) as a function of the applied current (0.5, 1.0 and 2.0 mA correspond to 2.55, 5.1 
and 10.2 mA/cm2, respectively). Timolol maleate (0.25% w/v) was delivered from a 
solution containing 77 mM NaCl and 25 mM Tris buffer at pH 7.0, while 
dexamethasone phosphate (0.4% w/v) was formulated in pure water alone (mean ± 
SD, n = 4). 
In vitro iontophoresis of dexamethasone phosphate across the sclera was also facile, and the 
fluxes achieved after one hour were directly proportional to the applied current (Figure 5). This 
behaviour has been observed for other drugs under similar conditions (e.g., sodium salicylate 
[9]). 
When dexamethasone phosphate was iontophoresed across the sclera at a fixed applied 
current of 1 mA (5.1 mA/cm2), but from solutions of the drug at different concentrations in 
water (from 0.1% to 2% w/v), the fluxes after 1 hour of current passage were essentially the 
                               
                           
                         
                           
                             
                         
                             
                                 






                       
                             
               
                                   
                         
                             
                                 
              
                   
                             
                             
                     
                       
                           
                     
                             
                     
                         
                         
                         
                         
                     
                         
same (Figure 6). In these experiments, the molar fraction of the drug in the donor, cathodal 
solution is effectively constant, in that there are no competing anions present. Only as 
iontophoresis proceeds are chloride ions ‘released’ into the drug solution from the Ag/AgCl 
electrochemistry at the cathode (and this may account for the slightly lower fluxes observed 
for the 0.1% and 0.4% w/v solutions). The results are in complete concordance with those 
recently reported on the iontophoretic delivery of dexamethasone across the skin when co‐ion 
competition is kept to an absolute minimum [21]. The deduced transport numbers of the drug 
at the four concentrations considered (0.1%, 0.4%, 1% and 2% w/v) were 4.0 (± 0.7)%, 4.2 (± 









Figure 6: Iontophoretic fluxes after 1 hour of cathodal iontophoresis of dexamethasone 
phosphate across rabbit sclera (area = 0.2 cm2) as a function of drug concentration in 
pure water (mean ± SD, n = 4). 
In vivo iontophoresis of timolol into the eyes of rabbits (n = 4) resulted an average (± SD) 
anterior segment concentration at 15 minutes post‐dosing of 160 (± 45) nmol/mL, equivalent 
to a substantial (and highly significant, p < 0.01) 42‐fold increase over that achieved passively 
with topical drops (3.9 (± 1.7) nmol/mL). The applied current in this experiment was 4 mA 
(corresponding to 4 mA/cm2) for 5 minutes. 
Trans‐scleral cathodal iontophoresis of dexamethasone phosphate in rabbits resulted in 
efficient drug delivery to both the anterior and posterior segments of the eye 15 minutes post‐
dosing (Figure 7). Further, at all three current intensities tested, the cumulative transport of 
dexamethasone and dexamethasone phosphate into the four ocular tissues examined was 
significantly higher than that achieved by passive diffusion (ANOVA followed by the Student‐
Newman‐Keuls test). The drug levels in the aqueous humour post‐iontophoresis were 50 to 
100‐fold higher than those reported after topical administration of 0.1% dexamethasone 
phosphate (two 25 µL drops administered 5 minutes apart) to New Zealand white rabbits [22]. 
The amounts of dexamethasone delivered to the vitreous humour by trans‐scleral 
iontophoresis corresponded to concentrations well above the 0.5 ‐ 2.5 nmol/mL range which is 
reported to be effective in suppressing inflammatory processes such as the production of 
cytokines, synthesis of prostaglandins, and migration of leukocytes [23]. These results are 
qualitatively consistent with an earlier investigation (also conducted in vivo in rabbits) of trans‐
scleral dexamethasone phosphate iontophoresis from a disposable hydrogel sponge [24]. In 
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same animal model have been shown to result in negligible levels of drug in both the vitreous 
humour and in the choroid‐retina [25]. 
However, dexamethasone and dexamethasone phosphate detected within the analyzed ocular 
tissues in the present study was relatively insensitive, as judged by an analysis of variance, to 
the level of the applied current. While it is impossible to deduce an unambiguous explanation 
for this observation, which appears at first glance to be at odds with the in vitro results 
described earlier, it is important to point out that, even in vitro, the cumulative amount of 
dexamethasone and dexamethasone phosphate (and the deduced drug flux at 5 minutes of 
current passage) detected in the receive chamber is also insensitive to the applied current. It 
seems reasonable to suggest that endogenous ions within the tissue are perhaps responsible 
for carrying the majority of the current flowing in the earliest moments of iontophoresis and 
that only after a certain time does the electrotransport of the drug become properly 
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Figure 7:	 Intraocular delivery of dexamethasone and dexamethasone phosphate (expressed in 
nanomoles) 15 minutes after either passive delivery or cathodal trans‐scleral 
iontophoresis (2, 4, or 6 mA (equivalent to 2, 4 or 6 mA/cm2) for 5 min of 4% w/v 
dexamethasone phosphate solution in New Zealand white rabbits (mean ± SD, n = 3 
for iontophoresis, n = 4 for passive delivery). The amounts of both dexamethasone 
and dexamethasone phosphate in each compartment were measured. “Total” 
corresponds to the sum of the amounts in the four tissues examined. 
The passive transport of vancomycin was below the limit of quantitation under the conditions 
of the in vitro experiments performed (see Supplementary Table S2). In contrast, the passive 
scleral delivery of high molecular weight, neutral dextrans has recently been reported to be 
relatively high [13]. Vancomycin, has a net positive charge at neutral pH, rendering it unlikely 
to partition into the scleral membrane in the absence of an electrical driving force. With 
iontophoresis, the flux of vancomycin did not increase linearly with increasing concentration in 
the driving electrode chamber (Figure 8). While transport increased significantly by about 10‐
fold when the peptide concentration was raised from 0.1 to 1 mM, subsequent elevation to 5 
and then 10 mM induced no further useful enhancement of flux. The flux of vancomycin after 
1 hour of iontophoresis at 0.5 mA (2.55 mA/cm2) was close to one‐half of that achieved when 
the applied current was increased to 1 mA (5.1 mA/cm2) (Figure 9). However, further 
increasing the current to 2 mA (10.2 mA/cm2) resulted in a dramatic decrease in 
electrotransport. 
                       
                         
                     
                         
                   
                         




                                 
                     
                             
                         








                                 
                           
                         
 
These behaviours have been observed in the transdermal iontophoresis of certain cationic 
peptides (e.g., Nafarelin and Leuprolide), and have been attributed to the association, and 
accumulation, of the positively‐charged permeant with fixed negative charges on the 
membrane [12,26]. This reduces the permselectivity of the barrier to cationic species, and 
compromises electroosmotic flow in the anode‐to‐cathode direction, i.e., the principal 
mechanism of electrotransport for these peptides [10]. It appears that a similar phenomenon 
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Figure 8:	 Trans‐scleral, anodal iontophoretic fluxes after 2 hours (at a current of 1 mA, i.e., 5.1 
mA/cm2) of vancomycin as a function of donor (anode chamber) concentration 
(mean ± SD, n = 4). Transport was significantly less when the drug donor 
concentration was 0.1 mM, but no significant differences in flux were discernible for 
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Figure 9:	 Anodal trans‐scleral iontophoretic flux of vancomycin (mean ± SD, n = 4), from a 5 
mM solution in 20 mM Tris/Trizma® HCl, as a function of applied current intensity 
(0.5, 1.0 and 2.0 mA correspond to 2.55, 5.1 and 10.2 mA/cm2, respectively). 
                        
                       
                         
                     
                     
                           
                     
                  
                   
                       
                             
                           
                         
                       
                         




                     




This research indicates that the results for trans‐scleral iontophoresis are broadly consistent 
with the well‐established principles for transdermal iontophoresis, and support the use of 
documented optimization strategies for trans‐scleral drug delivery. The sclera appears to be a 
cation‐permselective membrane, supporting a net negative charge at physiological pH. Drug 
transport numbers are optimized when competition from the background electrolyte is 
reduced. Iontophoretic fluxes are proportional to the applied current, at least for the tested 
small anionic and cationic drugs. Further work will explore drug structure‐transport 
relationships and the delivery of higher molecular weight species. 
Significant trans‐scleral delivery of timolol, dexamethasone phosphate, and vancomycin was 
achieved by iontophoresis. The results from the vancomycin experiments suggest that the 
peptide driving concentration and the applied current need to be judiciously chosen so as to 
optimise transport, and to avoid complications caused by association of the permeant with the 
membrane itself in a manner quite similar to that observed previously for transdermal 
iontophoresis of certain peptides. Interestingly, it may be possible to maximise vancomycin 
electrotransport with a lower concentration and a lesser applied current, clear advantages for 
the development of a practical ocular delivery system. 
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FIGURE LEGENDS
 
Figure 1: Schematic diagram of the ocular iontophoretic drug delivery device used in the in 
vivo experiments. The annular device comprises the following main elements: (1) 
proximal part which provides rigid support; (2) source connector pin between the 
current generator and the electrode; (3) electrode which transfers current to the 
formulation reservoir; (4) reservoir (17 mm OD x 14 mm ID x 3 mm H) which 
contains a polyurethane‐based foam insert saturated with a solution of the drug to 
be delivered; and (5) distal part, which is a soft plastic that interfaces with the eye. 
Figure 2: Upper panel: Electroosmotic flux of mannitol across rabbit sclera (area = 0.2 cm2) 
after 2 h of iontophoresis in the anode‐to‐cathode (open circles) and cathode‐to‐
anode (filled circles) directions (mean ± SD, n = 4). Lower panel: Anodal‐to‐
cathodal flux ratio of mannitol electroosmosis as a function of pH. The intersection 
of the line through the data with the x‐axis indicates the approximate pI of rabbit 
sclera. 
Figure 3: Anodal iontophoresis at 1 mA of timolol from a 0.25% w/v solution as a function of 
time and background electrolyte concentration (mean ± SD, n = 4). 
Figure 4: Cumulative delivery of timolol by anodal iontophoresis at 1 mA (5.1 mA/cm2) as a 
function of time and concentration from solutions containing 77 mM NaCl (mean ± 
SD, n = 4). 
Figure 5: Steady‐state iontophoretic fluxes of timolol maleate (dashed line) (r2 = 0.989) and 
dexamethasone phosphate (solid line) (r2 = 0.997) across rabbit sclera (area = 0.2 
cm2) as a function of the applied current (0.5, 1.0 and 2.0 mA correspond to 2.55, 
5.1 and 10.2 mA/cm2, respectively). Timolol maleate (0.25% w/v) was delivered 
from a solution containing 77 mM NaCl and 25 mM Tris buffer at pH 7.0, while 
dexamethasone phosphate (0.4% w/v) was formulated in pure water alone (mean 
± SD, n = 4). 
Figure 6: Iontophoretic fluxes after 1 hour of cathodal iontophoresis of dexamethasone 
phosphate across rabbit sclera (area = 0.2 cm2) as a function of drug concentration 
in pure water (mean ± SD, n = 4). 
Figure 7: Intraocular delivery of dexamethasone (expressed in nanomoles) 15 minutes after 
either passive delivery or cathodal trans‐scleral iontophoresis (2, 4, or 6 mA, 
(equivalent to 2, 4 or 6 mA/cm2) for 5 min of 4% w/v dexamethasone phosphate 
solution in New Zealand white rabbits (mean ± SD, n = 3 for iontophoresis, n = 4 
for passive delivery). The amounts of both dexamethasone and dexamethasone 
phosphate in each compartment were measured. . “Total” corresponds to the 
sum of the amounts in the four tissues examined. 
Figure 8: Trans‐scleral, anodal iontophoretic fluxes after 2 hours (at a current of 1 mA, i.e., 
5.1 mA/cm2) of vancomycin as a function of donor (anode chamber) concentration 
(mean ± SD, n = 4). Transport was significantly less when the drug donor 
concentration was 0.1 mM, but no significant differences in flux were discernible 
for the other three concentrations (ANOVA followed by Bonferroni post‐tests (p< 
0.05). 
Figure 9: Anodal trans‐scleral iontophoretic flux of vancomycin (mean ± SD, n = 4), from a 5 
mM solution in 20 mM Tris/Trizma® HCl, as a function of applied current intensity 
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Table S1:	 Passive fluxes of mannitol, dexamethasone and timolol across rabbit sclera from various 
donor solutions after 120, 60 and 120minutes of transport, respectively. 
Donor solution composition 
Passive flux 
nmol/min nmol/cm2/min 
Mannitol (1 mM) in 154 mM NaCl, buffered with 25 mM HEPES (pH 7.4) 0.09 ± 0.03 0.45 ± 0.14 
Dexamethasone (0.1% w/v) in water (pH 7.8) 0.03 ± 0.02 0.15 ± 0.09 
Dexamethasone (0.4% w/v) in water (pH 7.9) 0.21± 0.20 1.05 ± 0.98 
Dexamethasone (1% w/v) in water (pH 7.9) 0.52 ± 0.43 2.60 ± 2.14 
Dexamethasone (2% w/v) in water (pH 8.0) 0.05 ± 0.04 0.25 ± 0.20 
Timolol (0.25% w/v) in 10 mM NaCl (pH 4.4) 0.45 ± 0.32 2.25 ± 1.61 
Timolol (0.25% w/v) in 77 mM NaCl (pH 4.3) 0.43 ± 0.49 2.15 ± 2.50 
Timolol (0.25% w/v) in 154 mM NaCl (pH 4.4) 0.37 ± 0.33 1.85 ± 1.64 
Timolol (0.05% w/v) in 77 mM NaCl, buffered with 25 mM Tris (pH 7.0) 0.22 ± 0.15 1.10 ± 0.75 
Timolol (0.25% w/v) in 77 mM NaCl, buffered with 25 mM Tris (pH 7.0) 0.59 ± 0.30 2.95 ± 1.50 
Timolol (0.50% w/v) in 77 mM NaCl, buffered with 25 mM Tris (pH 7.0) 0.64 ± 0.51 3.20 ± 2.55 
Table S2: Passive fluxes of vancomycin across rabbit sclera from various donor solutions after 120 
minutes of transport. 
Donor solution composition 
Passive flux 
nmol/min nmol/cm2/min 
Vancomycin (0.1 mM) in 100 mM Tris/Trizma® HCl (pH 7.0) buffer  ‐*  ‐* 
Vancomycin (1 mM) in 100 mM Tris/Trizma® HCl (pH 7.0) buffer 0.04 ± 0.03 0.20 ± 0.15 
Vancomycin (5 mM) in 100 mM Tris/Trizma® HCl (pH 7.0) buffer 0.05 ± 0.03 0.25 ± 0.14 
Vancomycin (10 mM) in 100 mM Tris/Trizma® HCl (pH 7.0) buffer 0.05 ± 0.03 0.25 ± 0.15 
*not detectable 
